Effect of biodegradable polymer DES on maintenance hemodialysis patients with acute coronary syndrome
10.3969/j.issn.1004-8812.2014.10.001
- VernacularTitle:聚合物可降解支架对维持性血液透析合并急性冠状动脉综合征患者的疗效
- Author:
Geng WANG
;
Rui MA
;
Yaling HAN
;
Quanmin JING
;
Yingyan MA
;
Xiaozeng WANG
;
Bin WANG
- Publication Type:Journal Article
- Keywords:
Maintenance hemodialysis;
Acute coronary syndrome;
Drug-eluting stents
- From:
Chinese Journal of Interventional Cardiology
2014;(10):613-616
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effect of biodegradable polymer drug-eluting stents (DES) on maintenance hemodialysis (MHD) patients with acute coronary syndrome. Methods From 2008 January to 2013 July, a total of 100 MHD patients with ACS who were treated with PCI in our centre were randomly divided into two groups, 50 patients in the EXcellstent group (biodegradable polymer DES) and the others in the FIREBIRD stent group (Ordinary DES). The patients included 61 male and 39 female, while the mean age was (58.4±9.2) years old (43-74 years old). After procedure, the EXcellstent group patients took aspirin (100 mg qd) and clopidogrel (75 mg qd) for 6 months, then aspirin (100 mg qd) for lifelong. The FIRDBIRD stent group patients also took aspirin (100 mg qd) and clopidogrel (75 mg qd), then aspirin (100 mg qd) lifetime too. To observe the main adverse cardiovascular and cerebrovascular events (MACCE) and bleeding events during 12 months after procedure. Results The clinical data and angiographic results had no significant difference. No MACCE occurred during hospitalization. In 12 months after PCI, MACCE had no significant difference between two groups (P>0.05), and no stent thrombosis occured. One patient presented gastroin testinal bleeding in the EXcellgroup and 2 patients had cerebral hemorrhage in the FIRBIRD group. FIRBIRD group had more total hemorrhages events than that in EXcellgroup (P<0.05). Conclusions The treatment of biodegradable polymers DES in MHD patients with ACS was effective, and dual anti-platelet for 6 months was safe.
